Medesis Pharma

Medesis is a clinical development stage biopharmaceutical Company that is engaged through its unique and proven drug delivery technology – AONYS® – in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address major unmet medical needs.

Medesis disruptive new therapies are developed towards diseases with high unmet medical needs such as Alzheimer’s and Huntington’s diseases or type 2 diabetes.

Another strategic focus involves the development of three medical countermeasures for the protection of populations after a civil or military nuclear accident.

Early research programs are focused on oncology, dealing with multi-drug resistant cancers and the protection of healthy tissues during and after radiotherapy.